quinazolines has been researched along with Hepatitis C in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumert, TF; Duong, FH; Durand, SC; Fofana, I; Heim, MH; Lupberger, J; Pessaux, P; Thumann, C; Xiao, F; Zeisel, MB; Zona, L | 1 |
| He, PL; Hu, YH; Jing, JF; Li, YC; Tang, W; Tong, XK; Yu, Y; Zuo, JP | 1 |
| Barouch-Bentov, R; Berkerman, E; Einav, S; Mulholland, J; Neveu, G; Ziv-Av, A | 1 |
| Boerneke, MA; Charrette, BP; Hermann, T | 1 |
| Chang, KO; George, D; Patton, JB | 1 |
| Baumert, TF; Brino, L; Cosset, FL; Davis, C; Doffoël, M; Fischer, B; Fofana, I; Fresquet, J; Gorke, S; Lavillette, D; Lupberger, J; McKeating, JA; Mee, CJ; Patel, AH; Pessaux, P; Pietschmann, T; Poch, O; Raffelsberger, W; Rothenberg, SM; Royer, C; Thumann, C; Turek, M; Xiao, F; Zahid, MN; Zeisel, MB; Zona, L | 1 |
6 other study(ies) available for quinazolines and Hepatitis C
| Article | Year |
|---|---|
Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon-alpha; Liver Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2013 |
Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease.
Topics: Amides; Antiviral Agents; Cell Line; Drug Evaluation, Preclinical; Hepacivirus; Hepatitis C; Humans; Quinazolines; Viral Nonstructural Proteins | 2014 |
AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.
Topics: Blotting, Western; Cell Line; Erlotinib Hydrochloride; Hepacivirus; Hepatitis C; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Luciferases; Microscopy, Fluorescence; Plasmids; Protein Serine-Threonine Kinases; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Sunitinib; Virus Internalization | 2015 |
Ligand Optimization by Improving Shape Complementarity at a Hepatitis C Virus RNA Target.
Topics: Antiviral Agents; Benzimidazoles; Drug Design; Hepacivirus; Hepatitis C; Humans; Internal Ribosome Entry Sites; Ligands; Models, Molecular; Nucleic Acid Conformation; Quinazolines; RNA, Viral | 2016 |
Bile acids promote HCV replication through the EGFR/ERK pathway in replicon-harboring cells.
Topics: Antiviral Agents; Bile Acids and Salts; Cell Cycle; Cell Line; Chenodeoxycholic Acid; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Genes, Reporter; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interphase; Luciferases, Renilla; Promoter Regions, Genetic; Quinazolines; Transcriptional Activation; Tyrphostins; Viral Nonstructural Proteins; Virus Replication | 2011 |
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
Topics: Animals; Antigens, CD; Antiviral Agents; Base Sequence; Cell Line; Claudin-1; ErbB Receptors; Erlotinib Hydrochloride; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Ligands; Membrane Proteins; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, EphA2; RNA Interference; RNA, Small Interfering; Tetraspanin 28; Virus Internalization | 2011 |